What is the 13F Pro Quality Score for IPSC?

13F Pro ranks Century Therapeutics, Inc. (IPSC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IPSC's current score at https://13fpro.ai/research/IPSC (free sign-up required for the full ranking).

Where does 13F Pro source IPSC data?

All Century Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Century Therapeutics, Inc. files with the SEC under CIK 1850119. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IPSC in?

Century Therapeutics, Inc. (IPSC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IPSC research updated on 13F Pro?

IPSC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Century Therapeutics, Inc.(IPSC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1850119 IPSC stock profile & AI dashboard →

13F Pro Quality Score

43.5/100

Rank #1,812 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

99.9/100

Profitability

36.1/100

Balance Sheet

23.4/100

Earnings Quality

30.0/100

Free Cash Flow

9.2/100

Institutional Flow

99.8/100

Revenue Scale

25.4/100

Dilution Risk

22.7/100

IPSC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Century Therapeutics, Inc. (IPSC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IPSC at 43.5/100 on a 32-signal composite quality model, placing it at rank #1,812 of 2,879 stocks — the bottom half of the AI-ranked universe. IPSC scores in the top quartile across revenue growth (99.9), institutional flow (99.8). Areas of concern include free cash flow (9.2) and balance sheet strength (23.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 22.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Century Therapeutics, Inc. reports net income of $-21.6M, free cash flow of $-25.8M. Top institutional holders of IPSC by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., TCG Crossover Management,, Versant Venture Management,, based on the most recent SEC filings. IPSC trades on the Nasdaq exchange and files with the SEC under CIK 1850119. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IPSC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Century Therapeutics, Inc. directly from SEC EDGAR. Century Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 4 and 44 since 2023, currently 43.5 — an improving long-term trajectory across 22 quarterly and live scoring snapshots.

Net Income

Q1 2026

$-21.6M

Free Cash Flow

Q1 2026

$-25.8M

ROIC

Q1 2026

-8.9%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+194.8% YoY

$6.6MFY 2024

FY21 —FY22 $5.2MFY23 $2.2MFY24 $6.6M

Net Income

+7.4% YoY

$-126.6MFY 2024

FY21 $-95.8MFY22 $-130.9MFY23 $-136.7MFY24 $-126.6M

Operating Income

+5.7% YoY

$-138.1MFY 2024

FY21 $-94.9MFY22 $-133.8MFY23 $-146.5MFY24 $-138.1M

EPS (Diluted)

+30.0% YoY

$-0.81FY 2024

FY21 $-1.48FY22 $-1.48FY23 $-1.15FY24 $-0.81

Total Assets

-2.1% YoY

$353.2MFY 2024

FY21 $437.4MFY22 $486.5MFY23 $360.7MFY24 $353.2M

Total Debt

—FY 2024

FY21 $11.4MFY22 $16.9MFY23 —FY24 —

Op. Cash Flow

-24.7% YoY

$-110.1MFY 2024

FY21 $-89.0MFY22 $14.1MFY23 $-88.3MFY24 $-110.1M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$6.6M +194.8%	$2.2M -57.0%	$5.2M	—	—
Net Income	$-126.6M +7.4%	$-136.7M -4.4%	$-130.9M -36.6%	$-95.8M -78.9%	$-53.6M
Operating Income	$-138.1M +5.7%	$-146.5M -9.5%	$-133.8M -41.0%	$-94.9M -76.0%	$-53.9M
EPS (Diluted)	$-0.81 +30.0%	$-1.15 +22.3%	$-1.48 +0.0%	$-1.48 -4.0%	$-1.42
Total Assets	$353.2M -2.1%	$360.7M -25.9%	$486.5M +11.2%	$437.4M +309.6%	$106.8M
Total Debt	—	—	$16.9M +47.8%	$11.4M +18.7%	$9.6M
Operating Cash Flow	$-110.1M -24.7%	$-88.3M -728.7%	$14.1M +115.8%	$-89.0M -115.7%	$-41.3M

AI Insight: IPSC Financial Trends

Century Therapeutics posted $109M revenue in Q1 2026, matching Q1 2025 peak, but profitability collapsed and operating cash burn remained elevated.

• Revenue surged to $109M in Q1 2026, matching Q1 2025 level after six quarters near-zero sales.

• Operating losses narrowed to $21M in Q4 2025 from $37M in Q4 2024, showing improving cost discipline.

• Operating cash outflow averaged $26M in Q1 2026, consistent with Q4 2025, indicating sustained burn despite revenue.

⚠ Q1 2026 net loss of $22M despite $109M revenue signals massive gross margin or non-operating charges—critical disclosure gap.

⚠ Equity volatility: swung from $176M (Q3 2025) to $265M (Q1 2026)—likely stock issuance or one-time gain; sustainability unclear.

AI Insight: IPSC Ratio Trends

Century Therapeutics collapsed from Q1 2025 profitability to persistent losses across all metrics by Q1 2026.

• Operating margin swung from +68.0% in Q1 2025 to -21.7% in Q1 2026; NPM fell from +70.1% to -19.8%.

• ROE deteriorated from +127.4% (Q1 2025) to -32.7% (Q1 2026); ROA declined from +97.0% to -26.5%.

• ROIC collapsed from positive in Q1 2025 to -35.8% in Q1 2026, indicating capital destruction.

⚠ Q1 2025 profitability was an isolated spike—company returned to losses Q2 2025 onward with no recovery.

⚠ TTM metrics all deeply negative (OpMargin -105.5%, NPM -98.7%, ROIC -43.5%), suggesting structural unprofitability.

Get alerted when IPSC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Century Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IPSC

RA CAPITAL MANAGEMENT, L.P.
$40.1M17,754,430 sh
TCG Crossover Management, LLC
$39.0M17,754,430 sh
Versant Venture Management, LLC
$27.5M12,166,109 sh
Deep Track Capital, LP
$21.4M9,487,745 sh
Commodore Capital LP
$19.7M8,695,652 sh
RTW INVESTMENTS, LP
$19.7M8,695,652 sh
VR Adviser, LLC
$19.7M8,695,652 sh
Point72 Asset Management, L.P.
$13.5M5,964,678 sh
VANGUARD CAPITAL MANAGEMENT LLC
$12.9M5,686,204 sh
BALYASNY ASSET MANAGEMENT L.P.
$11.3M5,017,733 sh

Fund	Value	Shares
RA CAPITAL MANAGEMENT, L.P.	$40.1M	17,754,430
TCG Crossover Management, LLC	$39.0M	17,754,430
Versant Venture Management, LLC	$27.5M	12,166,109
Deep Track Capital, LP	$21.4M	9,487,745
Commodore Capital LP	$19.7M	8,695,652
RTW INVESTMENTS, LP	$19.7M	8,695,652
VR Adviser, LLC	$19.7M	8,695,652
Point72 Asset Management, L.P.	$13.5M	5,964,678
VANGUARD CAPITAL MANAGEMENT LLC	$12.9M	5,686,204
BALYASNY ASSET MANAGEMENT L.P.	$11.3M	5,017,733

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IPSC on your watchlist

Track score changes the day Century Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IPSC a good stock to buy?

13F Pro's AI-powered analysis of Century Therapeutics, Inc. (IPSC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IPSC are available on the IPSC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own IPSC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IPSC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Century Therapeutics, Inc.'s investment landscape.